Evidence map›Paper›PMID 40100528›Full record

ArticleGeroScience2025

Effect of acipimox on skeletal muscle biochemistry, structure and function in older people with probable sarcopenia: an experimental medicine study.

Claire McDonald, Craig Alderson, Matthew G Birkbeck, Silvia Del Din, Gráinne S Gorman, Kieren G Hollingsworth, Cameron Kirk, Clare Massarella, Lynn Rochester, Helen A L Tuppen and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in GeroScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Claire McDonaldAGE Research Group, Faculty of Medical Sciences, Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK. Claire.mcdonald@ncl.ac.uk.ORCID 0000-0002-7592-9952
Craig AldersonNewcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK.
Matthew G BirkbeckNewcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK.
Silvia Del DinNIHR Newcastle Biomedical Research Centre, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust and Newcastle University, Newcastle Upon Tyne, UK.
Gráinne S GormanNIHR Newcastle Biomedical Research Centre, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust and Newcastle University, Newcastle Upon Tyne, UK.
Kieren G HollingsworthNewcastle Magnetic Resonance Centre, Translational and Clinical Research Institute, Newcastle University, Tyne and Wear, Newcastle Upon Tyne, UK.
Cameron KirkBrain and Movement Research Group, Translational and Clinical Research Institute, Newcastle University, Tyne and Wear, Newcastle Upon Tyne, UK.
Clare MassarellaNIHR Newcastle Biomedical Research Centre, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust and Newcastle University, Newcastle Upon Tyne, UK.
Lynn RochesterNIHR Newcastle Biomedical Research Centre, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust and Newcastle University, Newcastle Upon Tyne, UK.
Helen A L TuppenWellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute, Newcastle University, Tyne and Wear, Newcastle Upon Tyne, UK.
Charlotte WarrenWellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute, Newcastle University, Tyne and Wear, Newcastle Upon Tyne, UK.
Avan A SayerAGE Research Group, Faculty of Medical Sciences, Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK.
Miles D WithamAGE Research Group, Faculty of Medical Sciences, Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSkeletal muscle nicotinamide adenine dinucleotide (NAD) concentrations are low in people with sarcopenia. Increasing NAD concentrations may offer a novel therapy. This study tested if acipimox (a NAD precursor) improves skeletal muscle NAD concentration and function in people with probable sarcopenia. Participants aged 65 and over with low walk speed (< 0.8 m/s) and low muscle strength (by 2019 European Working Group criteria) were recruited to this before and after, proof-of-concept study. Participants received acipimox 250 mg orally (twice or thrice daily according to creatinine clearance) + aspirin 75 mg daily (to prevent facial flushing) for 4 weeks. Muscle biopsy of the vastus lateralis, CLINICALTRIALS: gov Identifier: ISRCTN (ISRCTN87404878).

Indexed as

Muscle, SkeletalNADSarcopeniaAgedAged, 80 and overFemaleHumansMagnetic Resonance SpectroscopyMaleMuscle StrengthProof of Concept StudyWalking SpeedNADAcipimoxClinical trialNicotinamide adenine dinucleotideSarcopenia

Identifiers

PMID40100528
PMCPMC12397013

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.